Tongshang & Tongshang HK jointly represented Concord Healthcare Group in its HK IPO
On 9 January 2024, Eric Chow & Co. in Association with Commerce & Finance Law Offices (“Tongshang Hong Kong”), together with our PRC office, Commerce & Finance Law Offices (“Tongshang”), jointly represented Concord Healthcare Group Co., Ltd. (“Concord HC GP”, Stock Code: 02453.HK) in its listing and global offering of H shares on the Main Board of the Hong Kong Stock Exchange, with a market capitlisation of over HK$10 billion at the time of listing. CICC and Haitong International acted as the joint sponsors in this transaction.
Concord Healthcare Group Co., Ltd. is an oncology healthcare service provider in China serving both cancer patients and third-party medical institutions, with a market share of 0.5% in terms of revenue in 2022 in the private oncology healthcare service market in China, according to the F&S Report.
The collaboration between Tongshang and Tongshang Hong Kong has led to another successful achievement with the listing of Concord Healthcare. As the PRC and Hong Kong legal advisers for the issuer, we proudly provided “one-stop shop” comprehensive and high quality PRC and Hong Kong legal services.
Tongshang Hong Kong team was led by Managing Partner Eric Chow, Partners Clement Jiang and Brandon Chow, supported by Legal Assistant Ziwei Qiu.